In the evolving landscape of precision medicine, NET-targeted radiopharmaceuticals are emerging as pivotal tools for the diagnosis and treatment of a range of conditions, from heart failure and neurodegenerative disorders to neuroendocrine cancers. This review evaluates the advancements offered by ^(18)F-labeled PET tracers and ^(211)At alpha-particle therapy, juxtaposed with current ^(123)I-MIBG SPECT and ^(131)I-MIBG therapies. The enhanced spatial resolution and capability for …